Staphylococcus aureus is an important pathogen causing skin and soft-tissue infections, systemic infections and toxemic syndromes. In order to have adequate information for treatment of S. aureus infections, it is important to understand trends in the antibiotic-resistance patterns as well as clonal identities across geographical regions. A total of 20 non-duplicate S. aureus isolates (10 clinical, 4 carrier and 6 Methicillin-resistant S. aureus (MRSA) strains were resistant to at least 10 antibiotics including all penicillins, penicillin/penicillinase inhibitor combinations, carbapenem and cephalosporins. Methicillin-resistant Staphylococcus aureus (MRSA) is a bacterium responsible for several difficult-to-treat infections in humans. It is also called multidrug-resistant Staphylococcus aureus and oxacillin-resistant Staphylococcus aureus (ORSA). MRSA is any strain of Staphylococcus aureus that has developed, through the process of natural selection, resistance to beta-lactam antibiotics, which include the penicillins (methicillin, dicloxacillin, nafcillin, oxacillin, etc.) and the cephalosporins. Strains unable to resist these antibiotics are classified as Methicillin-sensitive Staphylococcus aureus, or MSSA. The evolution of such resistance does not cause the organism to be more intrinsically virulent than strains of Staphylococcus aureus that have no antibiotic resistance, but resistance does make MRSA infection more difficult to treat with standard types of antibiotics and thus more dangerous. MRSA is especially troublesome in hospitals, prisons and nursing homes, where patients with open wounds, invasive devices, and weakened immune systems are at greater risk of infection than the general public.